STAG2 and glioma: Mutations in STAG2 are associated with sensitivity to the PARP inhibitor olaparib, while CDKN2A deletions are associated with sensitivity to the CDK4/6 inhibitor palbociclib in glioma cell lines (Iorio et al., 2016).